Condoliase

Condoliase is a biopharmaceutical peptide for the treatment of lumbar disc herniation. Clinical trials have shown its benefit in alleviation of lumbar disc herniation associated low back pain and disability, although some concerns have been suggested with regard to promotion of disc degeneration.
Condoliase is derived from the enzyme mucopolysaccharidase from the Gram-negative bacteria Proteus vulgaris. It functions as an enzymatic chemonucleolysis product, specifically designed to reduce the size of the protruded herniation. It is an enzyme that specifically degrades glycosaminoglycans.
It was approved for use in Japan in 2018 as a treatment for lumbar disc herniation.